Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | PGD | P52209 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Hydroperoxide SCHEMBL27265843 | 0.80 | ALDH1A1 (0.53) | TSHRALDH1A1TP53MAPTPTGS1 | |
| Tert-Butyl Hydroperoxide SCHEMBL5147647 | 0.80 | ALDH1A1 (0.53) | TSHRALDH1A1TP53MAPTPTGS1 | |
| SCHEMBL6058611 | 0.79 | TSHR (0.50) | TSHRALDH1A1PGDTP53NFKB1 | |
| Tert-Butyl Hydroperoxide SCHEMBL2671237 | 0.78 | ALDH1A1 (0.69) | TSHRALDH1A1CYP2C19ALOX15GAA | |
| Tert-Butyl Hydroperoxide SCHEMBL538709 | 0.78 | ALDH1A1 (0.69) | TSHRALDH1A1CYP2C19ALOX15GAA | |
| Tert-Butyl Hydroperoxide SCHEMBL27609021 | 0.78 | ALDH1A1 (0.69) | TSHRALDH1A1CYP2C19ALOX15GAA | |
| Cadaverine Tartrate SCHEMBL11800555 | 0.77 | TSHR (0.62) | TSHRALDH1A1PGDTP53NFKB1 | |
| Tartaric Acid SCHEMBL31228716 | 0.77 | TSHR (0.62) | TSHRALDH1A1PGDTP53NFKB1 | |
| Cadaverine Tartrate SCHEMBL4367446 | 0.76 | TSHR (0.71) | TSHRPGDTP53NFKB1CYP2C19 | |
| Tert-Butyl Hydroperoxide SCHEMBL28376532 | 0.76 | ALDH1A1 (0.64) | TSHRALDH1A1CYP2C19ALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030091602-A1 | METHOD OF TREATING A COSMETIC COMPOSITION BY IRRADIATION WITH NIR RADIATION, AND ITS USE | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030091602-A1 | METHOD OF TREATING A COSMETIC COMPOSITION BY IRRADIATION WITH NIR RADIATION, AND ITS USE | CUTA, TYR, ASAH2 | TSHR 2096/4885ALDH1A1 595/4885PGD 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.